Search

everythingexperts & clinicslearnfaqsresearchcommunity

for

Search:↓

People are discussing their reactions if PP405 fails in phase 3 trials, with some expressing skepticism and others holding onto hope for future treatments like GT20029 and Breezula. Many mention continuing with existing treatments like minoxidil and finasteride, while others express disappointment and consider alternative solutions.

PP405 is a promising experimental topical treatment for alopecia that reactivates dormant hair follicles by targeting cellular energy, with large-scale trials planned for 2026. While it shows potential, it cannot regenerate permanently destroyed follicles, making hair transplants the only guaranteed solution for advanced baldness currently.

The conversation discusses various hair loss treatments, including Breezula, KX826, and PP405, with mixed opinions on their effectiveness compared to finasteride and minoxidil. Some users express skepticism about the new treatments, while others remain hopeful about future developments.

The user is using minoxidil, finasteride, dermarolling, and other treatments for hair regrowth, showing promising results in the temple area. Despite some skepticism, there is optimism about potential improvement.

The user is exploring hair loss treatments in China, currently using finasteride and minoxidil, and is concerned about seborrheic dermatitis. Clinics are recommending selenium sulfide, doxycycline, and mesotherapy ampoules like PT88/PT66 or SP88/SP66, but the user is unsure about their effectiveness.

The post discusses a theory that hair regrowth after transplant is due to the angiogenesis process (new blood vessels forming), not because the transplanted hair is unaffected by DHT. The responses highlight the established belief in 'donor dominance' (the importance of the hair's origin in transplantation) and skepticism about the new theory.

TDM-105795 is a potential hair growth stimulant that works differently from minoxidil and could be used alongside it for enhanced growth. It completed phase 2 trials in 2024, with a medium to high chance of release in 2026, but lacks recent updates or phase 3 trial information.

The conversation is about hair regrowth progress using hormone replacement therapy (HRT) with Estradiol and Cyproterone, without using Minoxidil. The user shares progress pictures over 0, 3, and 6 months.

Breezula (clascoterone) is expected to be available by late 2026, showing good long-term results with minimal side effects. KX-826 (pyrilutamide) acts faster but is still in earlier development stages.

A user shared progress pictures showing improvement from NW 6 to NW 2 after four months of treatment. They are considering using exosomes to further reverse hair miniaturization.

The user is using RU58841 for hair regrowth on the temples and is considering adding minoxidil. They are questioning the potential for vellus hairs to develop into fuller hair and the possibility of reactivating dormant follicles.

The conversation discusses the differences between KB solution and PG + Ethanol solution for RU58841 in treating hair loss. It compares the effectiveness and properties of these two solutions.

ET-02 is seen as promising for addressing hair loss and graying, but PP405 is more advanced in development and has better publicity. Some users plan to use both treatments alongside minoxidil and dutasteride.

A non-binary transfeminine person experienced significant hair regrowth after starting finasteride, minoxidil, microneedling, and hormone replacement therapy with estradiol. They encourage trans individuals concerned about hair loss to consider estrogen as it has greatly improved their hair condition.

The user is considering adding Stemoxydine to their hair loss regimen, as they already use topical finasteride with rosemary and cannot use Minoxidil. They are seeking feedback on Stemoxydine and Alphatradiol, and another user mentions 2-deoxy-d-ribose as a potential option.

RU58841 helped regrow hairline without side effects for a bodybuilder using PEDs. The treatment included RU58841, finasteride, minoxidil, GKH-Cu, microneedling, and HGH.

A transwoman is struggling with hair loss despite using hormones, dutasteride, and Abiraterone, and is considering making her own treatments due to difficulty accessing them. She has also tried Eucapil and regularly uses Nizoral shampoo.

2-Deoxy-D-Ribose (2dDR) is likely ineffective for treating hair loss and performs worse than 5% minoxidil. Finasteride and minoxidil are more effective treatments.

The conversation discusses an experiment involving hair loss treatments, including the use of Verteporfin, KY19382, dutasteride, oral and topical minoxidil, AHK-Cu, and microneedling. The experiment aims to test the effectiveness of these treatments in promoting hair growth and healing without scarring, with updates planned every few months.

Male pattern baldness (MPB) may be influenced by androgen receptors in scalp hair follicles and potentially poor blood flow. Transplanted hair is not immune to DHT, and factors like inflammation and scalp tension might also contribute to hair loss.

Exploring hair loss treatments beyond DHT, including Minoxidil, pyruvate, Gt20029 targeting androgen receptors, and vasodilators. Other options like Kx826, adenosine signaling, growth factor topicals, and microneedling are also discussed.

The conversation discusses hair loss treatments, specifically mentioning Minoxidil, finasteride, RU58841, and TB-500 Thymosin Beta-4. It critiques the credibility of biohacking claims.

A German startup, Mane Biotech, developed a head wearable device to reactivate hair follicle stem cells, sparking skepticism among users. Some users suspect it might be a scam, while others are interested in more information from the company's newsletter.

The user shared their hair regrowth journey using treatments like dutasteride, minoxidil, microneedling, tretinoin, Nizoral, silica, biotin, and hormone replacement therapy (HRT) with cyproterone and estradiol. They reported substantial hairline improvement and some crown thinning, with hopes for further progress.

Hair follicle stem cells remain in bald individuals, but progenitor cells do not, raising questions about hair regrowth claims by Pelage. PP405 is discussed as a potential treatment, with skepticism about its effectiveness compared to existing treatments like Minoxidil and Finasteride.

The user has been using a hair loss treatment regimen including RU58841, minoxidil, and dutasteride, but still experiences hairline recession and fatigue despite high testosterone levels. They are considering adjusting their dutasteride dosage due to concerns about libido and energy levels.

The conversation discusses topical androgen receptor blockers for hair loss, mentioning Clascoterone, Pyrilutamide, GT20029, and RU58841. Ketoconazole's effectiveness and application methods are also debated.

Betacarotene's effect on hair loss is discussed, with concerns about excessive vitamin A. The user also questions if 15mg melatonin impacts vitamin A levels.

A 26-year-old man shared his positive results after 10 months of treating male pattern baldness using a regimen that includes Estradiol Enanthate, DHPA, Bicalutamide, Dutasteride, oral and topical Minoxidil, and a dermaroller. He experienced mild gynecomastia and reduced body hair as side effects but was satisfied with the outcome.

The conversation discusses a personalized hair loss treatment plan based on DNA test results, recommending Minoxidil, Dutasteride, 17-alpha Estradiol, Cetirizine, and PRP sessions. The test identifies a high risk of hair loss due to DHT but a good response to Minoxidil, suggesting a tailored approach to treatment.